Human papilloma virus (HPV) is the primary cause of cervical cancer. With more than $6 million in support from the Foundation for NIH, investigators have expanded the scope of an existing National Cancer Institute (NCI) Phase III clinical trial examining a vaccine intended to prevent cervical and other cancers caused by this virus. The expansion makes possible validation, regulatory support and quality-assurance monitoring of the vaccine. The goal is to ensure that the resulting discoveries can be quickly translated into therapies that will prevent the spread of HPV.

Partners
GlaxoSmithKline Biologicals